5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

24/7 Wall Street • Dec 13, 2025

My Top 3 Healthcare Stocks to Buy in 2026

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas.

The Motley Fool • a day ago

AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock

AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

Zacks Investment Research • Dec 12, 2025

Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks

Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.

24/7 Wall Street • Dec 12, 2025

The Smartest Dividend Stocks to Buy With $5,000 Right Now

Bank of America's low payout ratio means this is a dividend you can count on. AbbVie's raking in money with immunology drugs Skyrizi and Rinvoq.

The Motley Fool • Dec 12, 2025

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.

MarketBeat • Dec 12, 2025

Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026

One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.

The Motley Fool • Dec 12, 2025

Is AbbVie Stock Too Cheap to Ignore at Today's Price?

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive.

The Motley Fool • Dec 11, 2025

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

Zacks Investment Research • Dec 11, 2025

This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.

24/7 Wall Street • Dec 10, 2025